The WI Child Psychiatry Consultation Program (WI CPCP) conference, both in-person and live online, will highlight the assessment of pre-psychosis and psychosis, next steps for suicidal pediatric patients, pediatric psychopharmacology, and substance abuse.

DOWNLOAD FLYER

REGISTER

Learning Objectives

Community Response Across the Spectrum of Psychosis

  • Recognize signs and symptoms of psychosis and the importance of early intervention.
  • Identify those at Clinical High Risk for Psychosis (CHR-P) and First Episode of Psychosis (FEP).
  • Understand assessment and resources for those meeting CHR-P and FEP criteria.

Next Steps with Suicidal Pediatric Patients in the Office 

  • Review suicide screening practices and evidence-based tools.
  • Explore brief and comprehensive suicide risk assessment strategies.
  • Identify next steps in patient care based on risk and available resources.

From Pre-K to SGAs: Pediatric Psychopharmacology Beyond the Basics 

  • How to approach using medications (clonidine, guanfacine, methylphenidate, mixed amphetamine salts) in children under 6 years old.
  • When to consider using more than one medication  (fluoxetine, sertraline, escitalopram, buspirone, bupropion, lamotrigine, mirtazapine) to treat a single mental illness in children.
  • When to consider using a second-generation antipsychotic (aripiprazole, risperidone, olanzapine, lurasidone), and what to consider first.

“Carts, Wax, Shatter, Dabs, and Zinners” Decoding and Treating Nicotine and Cannabis Use Disorders 

  • Identify Patterns of Use: Participants will learn to recognize the signs, symptoms, and patterns of nicotine and cannabis use in adolescents, including vaping, nicotine pouches, edibles and smoking while understanding the social and developmental factors contributing to dependence.
  • Implement Treatment Strategies: Participants will gain knowledge of evidence-based treatment approaches for adolescent nicotine and cannabis dependence, including behavioral counseling, pharmacotherapy options, and prevention techniques tailored to the unique challenges of this population.

Available credit:

  • 4.00 AAFP
  • 4.25 AMA PRA Category 1 Credit(s)™
  • 4.25 Hours of Participation
  • 1.00 NP Pharmacology
  • 4.00 NP Contact Hours
  • 4.00 PA